Imunon Inc

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IMUNON reports Q1 loss, highlights promising cancer treatment progress

IMUNON shows progress in clinical trials with promising data; strong leadership and innovative technology driving growth. Financial challenges exist, but opportunities in expanding therapeutic applications and COVID vaccine development are promising.

Imunon Inc reports Q2 losses, optimistic on clinical advancements

Imunon Inc faces financial challenges but shows promise in clinical outcomes.
Strategic expense management and positive study results are key strengths.
Opportunities lie in partnerships, financing, and upcoming data releases.
Leadership's optimism reflects confidence in the company's progress.

Imunon Inc reports positive clinical results and secures funding for growth

Imunon Inc's Q3 2024 performance reflects promising clinical advancements and financial stability, with plans for a Phase III trial in the pipeline.
The company's strengths lie in strong clinical data, secured funding, strategic partnerships, and a focus on innovation in cancer therapies.
Challenges include managing increased expenses, navigating partnerships, competition, and regulatory hurdles, requiring careful strategic planning.
Opportunities abound in advancing to Phase III trials, exploring partnerships for the COVID-19 vaccine, and leveraging strategic hires for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the IMUNON presentation will be available on the Events section of the Company's website beginning Monday, September 11 at 7:00 a.m. Eastern time.

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidate s in animal models

IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

Renowned scientist will advise on the development of IMUNON's FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the addition of Sachet A.

IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla

Imunon, Inc. (NASDAQ:IMNN ) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Corinne Le Goff – President, Chief Executive Officer Jeffrey Church - Chief Financial Officer Khursheed Anwer - Chief Science Officer Kim Golodetz - Investor Relations Conference Call Participants Emily Bodnar - HC Wainwright David Bautz - Zacks Kemp Dolliver - Brooklyn Capital Markets James Molloy - Alliance Global Partners Operator Good morning. My name is Alan, and I will be your operator today.

Imunon, Inc. (IMNN) Q2 2023 Earnings Call Transcript

Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that a manuscript titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer,” is available on the preprint server bioRxiv [here]. The study used IMUNON's proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination. These results add to the growing body of preclinical data confirming the efficacy and superior desirable features of the IMUNON's PlaCCine vaccine modality.

Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, August 10, 2023 to discuss financial results for the second quarter and six-months ended June 30, 2023 and provide an update on its clinical development of IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic non-viral and synthetic DNA technology for the expression of pathogen antigens, being evaluated in preclinical studies for the development of next-generation vaccines.

IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023

Production of c GMP Clinical Materials Supports R&D Efficiencies and Lower s Costs for Infectious Disease and Cancer Vaccines , and N on-viral DNA - based I mmuno- O ncology Therapies

IMUNON Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus

LAWRENCEVILLE, N.J., June 26, 2023 (GLOBE NEWSWIRE) -- Imunon, Inc.  (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 5,000 shares of common stock and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 1,000 shares of common stock as a material inducement to the employment to one individual hired by Imunon during the second quarter of 2023. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel discussion

IMUNON CEO to Discuss Company's Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023

Dr. Corinne Le Goff highlights clinical progress across the Company's pipeline , p rovides context on the promise of DNA as a therapeutic and a vaccine

IMUNON's CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention

New data show continued durability of response over 14 months with humoral immune responses increasing over time

IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023 and provide an update on its clinical development of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.

IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023

Findings from a m ouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies

IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001

Conference Call Begins Today at 11:00 a.m. Eastern Time

IMUNON Reports 2022 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 30, 2023 to discuss financial results for the fourth quarter and full year ended December 31, 2022 and provide an update on its clinical development of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.

IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023

Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality

IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023

LAWRENCEVILLE, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, today announced that an abstract related to the Company's DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19 at the Orange County Convention Center in Orlando, FL and virtually. The immunotherapy, IMNN-001 (formerly GEN-1), is currently in Phase 2 development for the localized treatment of advanced ovarian cancer.

IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Reviews 2022 accomplishments; sets forth 2023 milestones and long-term vision

IMUNON CEO Issues Letter to Shareholders

The study will be partially funded by Break Through Cancer through the Ovarian Minimal Residual Disease Team Lab

IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer

Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025 The sale of an additional $1.8 million of unused New Jersey NOLs expected in 2023

IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses

LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN ) , a clinical-stage drug development company, and The Wistar Institute, a global leader in biomedical research located in the heart of University City, Philadelphia, through its Vaccine & Immunotherapy Center, announce the signing of a first collaborative research agreement to research and develop new vaccine formulations utilizing IMUNON's PLACCINE modality for the development of vaccines for infectious diseases. IMUNON's platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems.

IMUNON Enters into Collaborative Research Agreement with The Wistar Institute's Vaccine & Immunotherapy Center to Research IMUNON's PLACCINE Vaccine Platform

LAWRENCEVILLE, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- I MUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 19,000 shares of common stock and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 4,000 shares of common stock as a material inducement to the employment to four individuals hired by IMUNON during the fourth quarter of 2022. The equity awards were approved in accordance with Nasdaq Listing Rule 5635 (c)(4).

News for Imunon Inc Stock (IMNN)